Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer.

Liu D, Qi X, Manjunath Y, Kimchi ET, Ma L, Kaifi JT, Staveley-O'Carroll KF, Li G.

J Immunol Res Ther. 2018;3(1):115-123. Epub 2018 Jun 8.

2.

Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Li G, Liu D, Cooper TK, Kimchi ET, Qi X, Avella DM, Li N, Yang QX, Kester M, Rountree CB, Kaifi JT, Cole DJ, Rockey DC, Schell TD, Staveley-O'Carroll KF.

J Hepatol. 2017 Jan;66(1):75-85. doi: 10.1016/j.jhep.2016.07.044. Epub 2016 Aug 9.

3.

Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF.

Oncoimmunology. 2017 Sep 21;7(1):e1372079. doi: 10.1080/2162402X.2017.1372079. eCollection 2017.

4.

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.

Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng AL.

Int J Cancer. 2014 Jan 15;134(2):319-31. doi: 10.1002/ijc.28362. Epub 2013 Jul 30.

5.

Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.

Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, Staveley-O'Carroll KF.

Hepatology. 2012 Jan;55(1):141-52. doi: 10.1002/hep.24652.

6.

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC.

Curr Cancer Drug Targets. 2011 Oct;11(8):944-53.

PMID:
21834756
7.

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.

Draghiciu O, Nijman HW, Hoogeboom BN, Meijerhof T, Daemen T.

Oncoimmunology. 2015 Jan 7;4(3):e989764. eCollection 2015 Mar.

8.

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH.

Cancer Res. 2009 Mar 15;69(6):2514-22. doi: 10.1158/0008-5472.CAN-08-4709. Epub 2009 Mar 10.

9.

The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.

Heine A, Schilling J, Grünwald B, Krüger A, Gevensleben H, Held SA, Garbi N, Kurts C, Brossart P, Knolle P, Diehl L, Höchst B.

Cancer Immunol Immunother. 2016 Mar;65(3):273-82. doi: 10.1007/s00262-015-1790-5. Epub 2016 Jan 19.

PMID:
26786874
10.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

11.

Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.

Chuang HY, Chang YF, Liu RS, Hwang JJ.

PLoS One. 2014 Oct 15;9(10):e109992. doi: 10.1371/journal.pone.0109992. eCollection 2014.

12.

Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.

Bagi CM, Gebhard DF, Andresen CJ.

Eur J Gastroenterol Hepatol. 2012 May;24(5):563-74. doi: 10.1097/MEG.0b013e328350916f.

PMID:
22314934
13.

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.

Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20.

14.

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.

Cao M, Xu Y, Youn JI, Cabrera R, Zhang X, Gabrilovich D, Nelson DR, Liu C.

Lab Invest. 2011 Apr;91(4):598-608. doi: 10.1038/labinvest.2010.205. Epub 2011 Feb 14.

15.

Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.

Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y.

JCI Insight. 2019 Aug 8;4(15). pii: 130116. doi: 10.1172/jci.insight.130116. eCollection 2019 Aug 8.

16.

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.

Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Chang LJ, Liu C, Nelson DR.

Cancer Immunol Immunother. 2013 Apr;62(4):737-46. doi: 10.1007/s00262-012-1380-8. Epub 2012 Dec 7.

17.

Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.

Abe F, Younos I, Westphal S, Samson H, Scholar E, Dafferner A, Hoke TA, Talmadge JE.

Int Immunopharmacol. 2010 Jan;10(1):140-5. doi: 10.1016/j.intimp.2009.09.023. Epub 2009 Oct 12.

PMID:
19833232
18.

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P.

Blood. 2008 Jun 15;111(12):5610-20. doi: 10.1182/blood-2007-02-075945. Epub 2008 Feb 29.

PMID:
18310500
19.

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.

Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J.

Gastroenterology. 2016 Jun;150(7):1646-1658.e17. doi: 10.1053/j.gastro.2016.02.040. Epub 2016 Feb 26.

20.

Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.

Laurila JP, Laukkanen MO, Joensuu H, Salmi M, Jalkanen S.

Int J Cancer. 2016 Nov 15;139(10):2270-6. doi: 10.1002/ijc.30285. Epub 2016 Aug 11.

Supplemental Content

Support Center